Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has extended its 13-year relationship with Tigermed, a leading global provider of clinical research solutions across the full life cycle of global biopharmaceutical and medical device products. This extended partnership will further harness the Medidata Platform from early-phase trials to post-marketing surveillance, to optimize study workflows, ensure regulatory compliance, and improve the speed of delivering new therapies to patients worldwide, including the emerging markets.
Since 2011, Tigermed has successfully completed over 300 clinical studies across diverse therapeutic areas, including oncology, vaccines, endocrine, and cardiovascular conditions, with the adoption of Medidata Platform. Built on a longstanding relationship, Tigermed will continue to leverage the Medidata Platform to seamlessly integrate with their workflow, automating data capture and streamlining operations traditionally reliant on labor-intensive CRO services. This collaboration will improve trial efficiency, connecting patients, sites, and sponsors, shortening time to market for new products.
“Our partnership with Medidata has allowed our customers to make informed, data-driven decisions and achieve milestones faster,” said Hao Wu, executive director and co-president, Tigermed. “We are delighted to extend this collaboration and look forward to leveraging more of Medidata’s technologies, including Medidata AI, as we shape the future of clinical trials worldwide.”
“Tigermed exemplifies the evolving role of CROs in driving efficiencies across the clinical trial process,” said Edwin Ng, senior vice president and general manager, APAC, Medidata. “Through this partnership, we’re able to jointly push the boundaries of trial management, improving the study experiences and ultimately delivering better outcomes for patients and sponsors around the world.”
